HeraMED Raises AU$3.2 Million to Advance Global Commercial Strategy.
HeraMED Limited (ASX: HMD) has received firm commitments to raise AU$3.2 million through a two-tranche placement, providing additional funding to progress the commercial rollout of its digital maternity and women’s health technology. The placement comprises 80.0 million new fully paid ordinary shares issued at AU$0.04 per share, representing an approximate 7.0% discount to the last traded price and consistent with the company’s recent VWAP.
The capital raising was supported by new institutional and sophisticated investors, alongside ongoing participation from existing shareholders, further strengthening the company’s investor base. Proceeds will be used to support working capital requirements and accelerate deployments, pilot programs and platform integration across the United States, Australia and Europe. The funding comes as HeraMED continues to build commercial momentum, supported by early agreements with large healthcare groups, positioning the company to execute near-term milestones and expand adoption of its digital care platform through the second half of FY26 and beyond.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
HeraMED Raises AU$3.2 Million to Advance Global Commercial Strategy.
HeraMED Limited (ASX: HMD) has received firm commitments to raise AU$3.2 million through a two-tranche placement, providing additional funding to progress the commercial rollout of its digital maternity and women’s health technology. The placement comprises 80.0 million new fully paid ordinary shares issued at AU$0.04 per share, representing an approximate 7.0% discount to the last traded price and consistent with the company’s recent VWAP.
The capital raising was supported by new institutional and sophisticated investors, alongside ongoing participation from existing shareholders, further strengthening the company’s investor base. Proceeds will be used to support working capital requirements and accelerate deployments, pilot programs and platform integration across the United States, Australia and Europe. The funding comes as HeraMED continues to build commercial momentum, supported by early agreements with large healthcare groups, positioning the company to execute near-term milestones and expand adoption of its digital care platform through the second half of FY26 and beyond.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au